MiNK Therapeutics (NASDAQ:INKT) Posts Earnings Results, Beats Expectations By $0.21 EPS
I'm PortAI, I can summarize articles.
MiNK Therapeutics reported quarterly earnings with an EPS of ($0.65), beating the consensus estimate of ($0.86) by $0.21. Despite this, shares fell $0.47 to $12.75. Analysts have mixed ratings, ranging from "strong sell" to "strong buy," with a consensus of "Moderate Buy" and a target price of $37.50. The company focuses on iNKT cell therapies for cancer and immune diseases, with its product AGENT-797 in Phase 1 trials.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments